ACE2 levels are altered in comorbidities linked to severe outcome in COVID-19
View ORCID ProfileValur Emilsson, View ORCID ProfileElias F Gudmundsson, View ORCID ProfileThor Aspelund, View ORCID ProfileBrynjolfur G Jonsson, View ORCID ProfileAlexander Gudjonsson, View ORCID ProfileLenore J. Launer, View ORCID ProfileJohn R Lamb, View ORCID ProfileValborg Gudmundsdottir, View ORCID ProfileLori L Jennings, View ORCID ProfileVilmundur Gudnason
doi: https://doi.org/10.1101/2020.06.04.20122044
Valur Emilsson
1Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
2Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
Elias F Gudmundsson
1Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
Thor Aspelund
1Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
Brynjolfur G Jonsson
1Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
Alexander Gudjonsson
1Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
Lenore J. Launer
3Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, MD 20892-9205, USA
John R Lamb
4GNF Novartis, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA.
Valborg Gudmundsdottir
1Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
2Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
Lori L Jennings
5Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, MA 02139, USA
Vilmundur Gudnason
1Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland
2Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
Data Availability
The custom-design Novartis SOMAscan is available through a collaboration agreement with the Novartis Institutes for BioMedical Research (lori.jennings{at}novartis.com). Data from the AGES Reykjavik study are available through collaboration (AGES_data_request{at}hjarta.is) under a data usage agreement with the IHA
Posted June 05, 2020.
ACE2 levels are altered in comorbidities linked to severe outcome in COVID-19
Valur Emilsson, Elias F Gudmundsson, Thor Aspelund, Brynjolfur G Jonsson, Alexander Gudjonsson, Lenore J. Launer, John R Lamb, Valborg Gudmundsdottir, Lori L Jennings, Vilmundur Gudnason
medRxiv 2020.06.04.20122044; doi: https://doi.org/10.1101/2020.06.04.20122044
ACE2 levels are altered in comorbidities linked to severe outcome in COVID-19
Valur Emilsson, Elias F Gudmundsson, Thor Aspelund, Brynjolfur G Jonsson, Alexander Gudjonsson, Lenore J. Launer, John R Lamb, Valborg Gudmundsdottir, Lori L Jennings, Vilmundur Gudnason
medRxiv 2020.06.04.20122044; doi: https://doi.org/10.1101/2020.06.04.20122044
Subject Area
Subject Areas
- Addiction Medicine (323)
- Allergy and Immunology (627)
- Anesthesia (163)
- Cardiovascular Medicine (2363)
- Dermatology (206)
- Emergency Medicine (378)
- Epidemiology (11755)
- Forensic Medicine (10)
- Gastroenterology (701)
- Genetic and Genomic Medicine (3720)
- Geriatric Medicine (348)
- Health Economics (632)
- Health Informatics (2387)
- Health Policy (929)
- Hematology (340)
- HIV/AIDS (780)
- Medical Education (365)
- Medical Ethics (104)
- Nephrology (398)
- Neurology (3481)
- Nursing (197)
- Nutrition (522)
- Oncology (1817)
- Ophthalmology (535)
- Orthopedics (218)
- Otolaryngology (286)
- Pain Medicine (232)
- Palliative Medicine (66)
- Pathology (445)
- Pediatrics (1030)
- Primary Care Research (418)
- Public and Global Health (6128)
- Radiology and Imaging (1274)
- Respiratory Medicine (825)
- Rheumatology (379)
- Sports Medicine (322)
- Surgery (400)
- Toxicology (50)
- Transplantation (171)
- Urology (145)